Trial · NCT01210482
Adverse events189
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 189
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Stomatitis | Gastrointestinal disorders | TORISEL Injection (Temsirolimus) | 257 | 1,001 | |
| other | Anaemia | Blood and lymphatic system disorders | TORISEL Injection (Temsirolimus) | 59 | 1,001 | |
| other | Pyrexia | General disorders | TORISEL Injection (Temsirolimus) | 54 | 1,001 | |
| other | Platelet count decreased | Investigations | TORISEL Injection (Temsirolimus) | 104 | 1,001 | |
| other | Hypercholesterolaemia | Metabolism and nutrition disorders | TORISEL Injection (Temsirolimus) | 56 | 1,001 | |
| other | Hyperglycaemia | Metabolism and nutrition disorders | TORISEL Injection (Temsirolimus) | 93 | 1,001 | |
| other | Hyperlipidaemia | Metabolism and nutrition disorders | TORISEL Injection (Temsirolimus) | 60 | 1,001 | |
| other | Rash | Skin and subcutaneous tissue disorders | TORISEL Injection (Temsirolimus) | 76 | 1,001 | |
| serious | Shock | Vascular disorders | TORISEL Injection (Temsirolimus) | 1 | 1,001 | |
| serious | Flushing | Vascular disorders | TORISEL Injection (Temsirolimus) | 1 | 1,001 | |
| serious | Deep vein thrombosis | Vascular disorders | TORISEL Injection (Temsirolimus) | 1 | 1,001 | |
| serious | Stevens-Johnson syndrome | Skin and subcutaneous tissue disorders | TORISEL Injection (Temsirolimus) | 1 | 1,001 | |
| serious | Rash | Skin and subcutaneous tissue disorders | TORISEL Injection (Temsirolimus) | 1 | 1,001 | |
| serious | Erythema multiforme | Skin and subcutaneous tissue disorders | TORISEL Injection (Temsirolimus) | 2 | 1,001 | |
| serious | Drug eruption | Skin and subcutaneous tissue disorders | TORISEL Injection (Temsirolimus) | 1 | 1,001 | |
| serious | Dermatitis allergic | Skin and subcutaneous tissue disorders | TORISEL Injection (Temsirolimus) | 1 | 1,001 | |
| serious | Dermatitis acneiform | Skin and subcutaneous tissue disorders | TORISEL Injection (Temsirolimus) | 1 | 1,001 | |
| serious | Sputum retention | Respiratory, thoracic and mediastinal disorders | TORISEL Injection (Temsirolimus) | 1 | 1,001 | |
| serious | Respiratory tract inflammation | Respiratory, thoracic and mediastinal disorders | TORISEL Injection (Temsirolimus) | 1 | 1,001 | |
| serious | Respiratory failure | Respiratory, thoracic and mediastinal disorders | TORISEL Injection (Temsirolimus) | 5 | 1,001 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01210482/events